RORA and metabolic disease: However, these studies raise the possibility of a novel therapeutic strategy for metabolic disorders: the development of small molecules to manipulate the circadian clock—for example, the REV-ERB agonist SR9009, GSK4112 and the RORα inverse agonist SR3335 were used to improve metabolic disorders in rodents [21,22].